<DOC>
	<DOCNO>NCT03021291</DOCNO>
	<brief_summary>This study design assess effect Gelesis100 body weight additional exposure 24 week subject complete 24-week treatment period , least 3 % weight loss , Gelesis Loss Of Weight GLOW , NCT02307279 ) study .</brief_summary>
	<brief_title>Extension Study Gelesis100 Body Weight</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<criteria>1 . Completion GLOW study least 3 % weight loss 2 . Informed Consent Form sign subject end GLOW study 1 . Pregnancy ( positive serum urine pregnancy test ( ) females childbearing potential ) lactation 2 . Absence medically approve contraceptive method female childbearing potential ( e.g. , hysterectomy , nonoral contraceptive medication intrauterine device combine barrier method , two combine barrier method diaphragm condom spermicide , condom spermicide ; bilateral tubal ligation vasectomy acceptable contraceptive method ) 3 . Subjects consider smoke cessation study 4 . Subjects anticipate surgical intervention study 5 . Significant intolerance study product GLOW study 6 . Increase ≥ 0.5 % point ( ≥ 5.5 mmol/mol ) HbA1c Baseline Visit GLOW study subject treat untreated type 2 diabetes consider clinically relevant , increase HbA1c &gt; 8.5 % ( &gt; 69 mmol/mol ) 7 . Increase ≥ 10 % total cholesterol , lowdensity lipoprotein ( LDL ) cholesterol , triglyceride Baseline Visit GLOW study subject elevate lipid Baseline Visit GLOW study consider clinically relevant , increase serum LDL cholesterol ≥ 190 mg/dL ( ≥ 4.93 mmol/L ) and/or serum triglyceride ≥ 500 mg/dL ( ≥ 5.65 mmol/L ) 8 . Increase ≥ 10 mm Hg supine systolic blood pressure ( SBP ) and/or supine diastolic blood pressure ( DBP ) Baseline Visit GLOW study subject treat untreated hypertension consider clinically relevant , increase supine SBP &gt; 160 mm Hg and/or supine DBP &gt; 95 mm Hg , base mean two consecutive reading 9 . Poor subject compliance GLOW study procedure recommendation and/or major protocol deviation 10 . Anticipated requirement use prohibit concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>